日光性角化症治疗市场－全球产业规模、份额、趋势、机会和预测，依治疗方法、药物类别、最终用户、地区和竞争格局划分，2020-2030年预测

全球光化性角化症治疗市场规模将从2024年的69.2亿美元成长到2030年的92.5亿美元，复合年增长率为4.95%。全球光化性角化症（AK）治疗市场涵盖药物介入（如外用药物和光动力疗法）以及手术切除等外科治疗方法，所有这些方法都旨在治疗主要由慢性紫外线照射引起的癌前皮肤病变。

主要市场驱动因素

全球光化性角化症治疗市场主要受光化性角化症患者病率上升和全球人口老化的影响。光化性角化症发生率的增加直接扩大了需要诊断和治疗的患者群体。

主要市场挑战

熟练的皮肤科专家和合格的医疗保健人员持续短缺，严重阻碍了全球光化性角化病治疗市场的发展。这种短缺直接限制了治疗的普及，并导致患者治疗的严重延误。

主要市场趋势

新型局部和全身疗法的出现，显着推动了全球光化性角化病治疗市场的发展，这些疗法引入了疗效更佳、副作用更少、作用机制创新的先进药物。这些新疗法通常能够弥补现有疗法的不足，为皮肤科医生提供更广泛的选择，从而製定更个人化的患者治疗方案，并有可能提高疾病清除率。

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：顾客之声

第五章：全球日光性角化症治疗市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依治疗方法（局部治疗、手术、光动力疗法）
  • 依药物类别（核苷代谢抑制剂、非类固醇抗发炎药、免疫反应调节剂、光增强剂、其他）
  • 按最终使用者（医院和诊所、门诊中心、其他）
  • 按地区
  • 按公司（2024 年）
• 市场地图

第六章：北美日光性角化症治疗市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲日光性角化症治疗市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区日光性角化症治疗市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东及非洲日光性角化症治疗市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第十章：南美洲日光性角化症治疗市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章：市场动态

• 司机
• 挑战

第十二章：市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章：全球日光性角化症治疗市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商议价能力
• 顾客的力量
• 替代产品的威胁

第十五章：竞争格局

• Almirall SA
• LEO Pharma A/S
• Sun Pharmaceutical Industries Ltd.
• Novartis AG
• GALDERMA SA
• Ortho Dermatologics (Bausch Health Companies Inc.)
• BIOFRONTERA AG
• Hill Dermaceuticals, Inc.

第十六章：策略建议

第17章调查会社について・免责事项

The Global Actinic Keratosis Treatment Market will grow from USD 6.92 Billion in 2024 to USD 9.25 Billion by 2030 at a 4.95% CAGR. The global actinic keratosis (AK) treatment market encompasses pharmaceutical interventions, such as topical medications and photodynamic therapy, alongside procedural approaches like cryotherapy and surgical excision, all aimed at addressing precancerous skin lesions primarily induced by chronic ultraviolet exposure.

Key Market Drivers

The global actinic keratosis treatment market is significantly propelled by the rising prevalence of actinic keratosis and the aging global population. The increasing incidence of actinic keratosis directly expands the patient pool requiring diagnosis and therapeutic intervention. According to the British Journal of Dermatology, March 2024, in "Global epidemiology of actinic keratosis in the general population: a systematic review and meta-analysis", the global prevalence rate for actinic keratosis is 14%, indicating a substantial disease burden worldwide.

Key Market Challenges

The persistent lack of skilled dermatology specialists and qualified healthcare providers significantly impedes the growth of the global actinic keratosis treatment market. This shortage directly limits treatment penetration and causes substantial delays in patient care. Across various regions, the inadequate availability of specialists means fewer individuals receive timely diagnosis and appropriate therapeutic interventions for precancerous skin lesions.

Key Market Trends

The emergence of novel topical and systemic therapies significantly drives the global actinic keratosis treatment market by introducing advanced agents with improved efficacy, reduced side effects, and innovative mechanisms of action. These new treatments often address limitations of existing options, providing dermatologists with a broader range of choices for tailored patient care and potentially higher clearance rates.

Key Market Players

• Almirall S.A.
• LEO Pharma A/S
• Sun Pharmaceutical Industries Ltd.
• Novartis AG
• GALDERMA SA
• Ortho Dermatologics (Bausch Health Companies Inc.)
• BIOFRONTERA AG
• Hill Dermaceuticals, Inc.

Report Scope:

In this report, the Global Actinic Keratosis Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Actinic Keratosis Treatment Market, By Therapy:

• Topical
• Surgery
• Photodynamic Therapy

Actinic Keratosis Treatment Market, By Drug Class:

• Nucleoside metabolic inhibitor
• NSAIDS
• Immune response modifiers
• Photoenhancers
• Others

Actinic Keratosis Treatment Market, By End User:

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Actinic Keratosis Treatment Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Actinic Keratosis Treatment Market.

Available Customizations:

Global Actinic Keratosis Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Actinic Keratosis Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Therapy (Topical, Surgery, Photodynamic Therapy)
  • 5.2.2. By Drug Class (Nucleoside metabolic inhibitor, NSAIDS, Immune response modifiers, Photoenhancers, Others)
  • 5.2.3. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Actinic Keratosis Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Therapy
  • 6.2.2. By Drug Class
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Actinic Keratosis Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Therapy
      • 6.3.1.2.2. By Drug Class
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Actinic Keratosis Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Therapy
      • 6.3.2.2.2. By Drug Class
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Actinic Keratosis Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Therapy
      • 6.3.3.2.2. By Drug Class
      • 6.3.3.2.3. By End User

7. Europe Actinic Keratosis Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Therapy
  • 7.2.2. By Drug Class
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Actinic Keratosis Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Therapy
      • 7.3.1.2.2. By Drug Class
      • 7.3.1.2.3. By End User
  • 7.3.2. France Actinic Keratosis Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Therapy
      • 7.3.2.2.2. By Drug Class
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Actinic Keratosis Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Therapy
      • 7.3.3.2.2. By Drug Class
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Actinic Keratosis Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Therapy
      • 7.3.4.2.2. By Drug Class
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Actinic Keratosis Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Therapy
      • 7.3.5.2.2. By Drug Class
      • 7.3.5.2.3. By End User

8. Asia Pacific Actinic Keratosis Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Therapy
  • 8.2.2. By Drug Class
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Actinic Keratosis Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Therapy
      • 8.3.1.2.2. By Drug Class
      • 8.3.1.2.3. By End User
  • 8.3.2. India Actinic Keratosis Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Therapy
      • 8.3.2.2.2. By Drug Class
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Actinic Keratosis Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Therapy
      • 8.3.3.2.2. By Drug Class
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Actinic Keratosis Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Therapy
      • 8.3.4.2.2. By Drug Class
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Actinic Keratosis Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Therapy
      • 8.3.5.2.2. By Drug Class
      • 8.3.5.2.3. By End User

9. Middle East & Africa Actinic Keratosis Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Therapy
  • 9.2.2. By Drug Class
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Actinic Keratosis Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Therapy
      • 9.3.1.2.2. By Drug Class
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Actinic Keratosis Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Therapy
      • 9.3.2.2.2. By Drug Class
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Actinic Keratosis Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Therapy
      • 9.3.3.2.2. By Drug Class
      • 9.3.3.2.3. By End User

10. South America Actinic Keratosis Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Therapy
  • 10.2.2. By Drug Class
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Actinic Keratosis Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Therapy
      • 10.3.1.2.2. By Drug Class
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Actinic Keratosis Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Therapy
      • 10.3.2.2.2. By Drug Class
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Actinic Keratosis Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Therapy
      • 10.3.3.2.2. By Drug Class
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Actinic Keratosis Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Almirall S.A.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. LEO Pharma A/S
• 15.3. Sun Pharmaceutical Industries Ltd.
• 15.4. Novartis AG
• 15.5. GALDERMA SA
• 15.6. Ortho Dermatologics (Bausch Health Companies Inc.)
• 15.7. BIOFRONTERA AG
• 15.8. Hill Dermaceuticals, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer